news-med.jpg

Evotec reports First Quarter 2018 results and provides Corporate update

55% increase in Group revenues Strong underlying operational performance with new business mix after Aptuit acquisition “3X30” outlook for 2018 confirmed Webcast and conference call today at 02.00 pm CEST

Topics: Corporate, first quarter update, 2018 results Read More

Evotec and Carna Biosciences collaborate on INDiGO platform

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing ...

Topics: Corporate, INDiGO, Carna Biosciences, Blood cancer Read More

Evotec expands CRISPR-based technology offering with licence from ERS genomics

Hamburg, Germany, 02 May 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene ...

Topics: Corporate, genomics, technology, crispr Read More

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Hamburg, Germany, 18 April 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive ...

Topics: Corporate, Bayer, Endometriosis, Phase I Read More

Evotec forms collaboration with Petra Pharma on INDiGO platform

Petra Pharma Corporation to harness Evotec's INDiGO platform to accelerate its lead programme (Petra-01 for oncology indications) through IND filing Evotec eligible to receive success-based milestones and research funding Evotec's INDiGO, a key value-driving component of its EVT Execute business ...

Topics: Corporate, INDiGO Read More

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

INDiGO® is the market leading integrated drug development solution that accelerates drug candidate delivery from candidate selection through to IND submission in typically less than 52 weeks.

Topics: Corporate, INDiGO Read More

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Hamburg, Germany and Vienna, Austria, 08 January 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party ...

Topics: Corporate, Apeiron, Sanofi, pre-clinical development, immuno-oncology Read More

Evotec Enters into Research Collaboration with CRTD to Discover Novel Therapies for Retinal Diseases

COLLABORATION HIGHLIGHTS EVT INNOVATE’S BUSINESS MODEL TO ACCESS LEADING ACADEMIC EXPERTISE CRTD’S NEXT GENERATION STEM CELL MODELLING WILL ACCELERATE EVOTEC’S ABILITY TO DISCOVER NEW RETINAL DISEASE DRUGS Dresden and Hamburg, Germany, 13 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, ...

Topics: Corporate, Research collaboration, Retinal diseases Read More

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 ...

Topics: Corporate, Drug Discovery Read More

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues ...

Topics: Corporate, Business, Drug Discovery, Contract Reseach Organization, Respiratory Read More